Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N -acetyl galactosamine improves potency 10-fold in mice

Abstract

Triantennary N-acetyl galactosamine (GalNAc, GN3), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), enhances the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6–10-fold in mouse liver. When combined with next-generation ASO designs comprised of short S-cEt (S-2′-O-Et-2′,4′-bridged nucleic acid) gapmer ASOs, ∼60-fold enhancement in potency relative to the parent MOE (2′-O-methoxyethyl RNA) ASO was observed. GN3-conjugated ASOs showed high affinity for mouse ASGPR, which results in enhanced ASO delivery to hepatocytes versus non-parenchymal cells. After internalization into cells, the GN3-ASO conjugate is metabolized to liberate the parent ASO in the liver. No metabolism of the GN3-ASO conjugate was detected in plasma suggesting that GN3 acts as a hepatocyte targeting prodrug that is detached from the ASO by metabolism after internalization into the liver. GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice. The unconjugated ASOs are currently in late stage clinical trials for the treatment of familial chylomicronemia and TTR-mediated polyneuropathy. The ability to translate these observations in humans offers the potential to improve therapeutic index, reduce cost of therapy and support a monthly dosing schedule for therapeutic suppression of gene expression in the liver using ASOs.

Cited by papers we hold 9

• Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines · 2025
  No notice
• Trials and Tribulations of MicroRNA Therapeutics · 2024
  No notice
• Antisense oligonucleotides: a novel Frontier in pharmacological strategy · 2023
  No notice
• Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras · 2023
  No notice
• The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery · 2021
  No notice
• The powerful world of antisense oligonucleotides: From bench to bedside · 2020
  No notice
• Therapeutic siRNA: state of the art · 2020
  No notice
• Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle · 2019
  No notice
• Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.